HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report.

Abstract
This prospective evaluation of 5-fluorouracil (5-FU) and methyl-CCNU administered in combination to patients with surgery for histologically proved gastric adenocarcinoma is based upon 312 patients randomized between August 1974 and May 1980. Patients were stratified into three categories of resectability, (1) complete, (2) proven incomplete, and (3) nonresectable, prior to random treatment assignment to surgery alone or surgery followed by adjuvant chemotherapy. Drug therapy consisted of discrete 5-day courses administered at 7-week intervals. Toxic reactions were reported in association with 42% of the courses. Treatment was suspended or discontinued in 6% of the courses because of hematologic toxicity. Treated patients with curative resections experienced a more favorable survival than did controls, but the early advantage was lost by the end of the second follow-up year. However, no statistically significant improvements in survival or reductions in risks of recurrence were observed. Similar proportions of treated and control deaths were attributable to residual or recurrent disease.
AuthorsG A Higgins, J H Amadeo, D E Smith, E W Humphrey, R J Keehn
JournalCancer (Cancer) Vol. 52 Issue 6 Pg. 1105-12 (Sep 15 1983) ISSN: 0008-543X [Print] United States
PMID6349780 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Nitrosourea Compounds
  • Semustine
  • Fluorouracil
Topics
  • Adenocarcinoma (drug therapy, mortality, surgery)
  • Aged
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Fluorouracil (administration & dosage)
  • Gastrectomy
  • Humans
  • Laparotomy
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Nitrosourea Compounds (administration & dosage)
  • Probability
  • Random Allocation
  • Semustine (administration & dosage)
  • Stomach Neoplasms (drug therapy, mortality, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: